Impact of HIV and treatment on brain development in adolescents
Effects of HIV and ART on myelination in the adolescent
This study is looking at how HIV and its treatment can impact brain development in young people aged 12 to 24, helping us understand why they might face challenges with thinking and behavior, so we can better support their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11031429 on NIH RePORTER |
What this research studies
This research investigates how HIV infection and antiretroviral therapy (ART) affect brain development in adolescents aged 12 to 24. It focuses on understanding the mechanisms behind cognitive and behavioral impairments that may arise during this critical developmental period. By examining the effects of the virus and treatment on myelination and synaptic pruning, the study aims to uncover the reasons behind higher rates of neurocognitive disorders in young people living with HIV. Participants may undergo assessments to evaluate brain function and structure, contributing to a better understanding of their unique health needs.
Who could benefit from this research
Good fit: Ideal candidates for participation are adolescents and young adults aged 12 to 24 who are living with HIV, particularly those receiving or not receiving ART.
Not a fit: Patients who are not living with HIV or who are outside the age range of 12 to 24 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that better support the cognitive and behavioral health of adolescents living with HIV.
How similar studies have performed: Previous research has indicated significant cognitive and behavioral challenges in young adults with HIV, suggesting that this area of investigation is both relevant and necessary.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Jordan-Sciutto, Kelly L — University of Pennsylvania
- Study coordinator: Jordan-Sciutto, Kelly L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.